Literature DB >> 2115160

Tissue plasminogen activator in the treatment of superior vena caval thrombosis associated with parenteral nutrition.

G R Barclay1, K Allen, C R Pennington.   

Abstract

Two patients, one of whom was pregnant, developed superior vena caval thrombosis while receiving central parenteral nutrition. They were successfully treated with recombinant tissue plasminogen activator (t-PA).

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2115160      PMCID： PMC2426832          DOI： 10.1136/pgmj.66.775.398

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

Review 1.  Plasminogen activators. The old and the new.

Authors:  M S Runge; T Quertermous; E Haber
Journal:  Circulation       Date:  1989-02       Impact factor: 29.690

Review 2.  Tissue plasminogen activator.

Authors:  J Loscalzo; E Braunwald
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

3.  Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients.

Authors:  F Bozzetti; D Scarpa; G Terno; A Scotti; M Ammatuna; M G Bonalumi; E Ceglia
Journal:  JPEN J Parenter Enteral Nutr       Date:  1983 Nov-Dec       Impact factor: 4.016

4.  Long-term parenteral nutrition. II. Catheter-related complications.

Authors:  K Ladefoged; F Efsen; J Krogh Christoffersen; S Jarnum
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

5.  Thrombosis of superior vena cava during total parenteral nutrition, managed successfully with low dose streptokinase.

Authors:  A Halevy; Y Leonov; G Lewinsohn; E Witz; R Orda
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440
  5 in total
  2 in total

1.  The state and quantitative characterization of congested capillaries in the brain in conditions of acute and chronic venous congestion.

Authors:  S V Chemezov
Journal:  Neurosci Behav Physiol       Date:  2000 Jan-Feb

Review 2.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.